探索被诊断患有子宫癌的美国西班牙裔群体 - 有没有差异?
Megan Reddy1, Chunqiao Tian2, Chen-I Liao3
1California Pacific Medical Center, 795 El Camino Real, San Francisco, CA 94109, USA.
Gynecologic oncology
|December 27, 2023
概括
在西班牙裔人口中,子宫癌的发病率正在上升,特别是在多米尼加妇女中,她们的疾病发病率和侵袭性亚型更高. 肥胖可能起到作用,特别是在波多黎各,多米尼加共和国和墨西哥的西班牙裔子群体中.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 在不同的人口群体中,子宫癌的发病率和趋势在不同的人口群体中有很大差异.
- 了解这些差异对于有针对性的公共卫生干预和癌症预防策略至关重要.
研究的目的:
- 调查美国各种西班牙裔子群体的子宫癌发病率和组织学模式和趋势.
- 确定具有最高子宫癌负担的特定西班牙裔子组,并探索潜在的促成因素,如肥胖.
主要方法:
- 利用美国癌症统计局 (USCS) 和国家癌症数据库 (NCDB) 的发生率,人口统计和组织学数据.
- 用户joinpoint回归用于对2001-2017年 (USCS) 和2004-2015年 (NCDB) 趋势的统计分析.
- 纳入世界人口审查数据 (2023) 关于相关西班牙裔子组的肥胖率.
主要成果:
- 与非西班牙裔白人 (23.29/100,000) 相比,西班牙裔女性的子宫癌总发病率较高 (27.46/100,000).
- 在西班牙裔 (1.94%) 与白人 (0.85%) 的年均发病率增加是两倍以上,具有显著的攻击性组织学亚型的显著增加.
- 多米尼加妇女的诊断增加最大,疾病发病比例最高 (28.0%),非子宫内膜组织学发生率最高 (37.1%).
- 在波多黎各 (51.4%),多米尼加共和国 (34.1%) 和墨西哥 (32.8%) 观察到高女性肥胖率.
结论:
- 在西班牙裔人口中,子宫癌的发病率正在增加,多米尼加妇女面临着不成比例地更高的晚期疾病和侵略性亚型的负担.
- 在西班牙裔子群体,特别是多米尼加人中,子宫癌的显著增加需要进一步研究导致的因素.
- 肥胖对波多黎各人,多米尼加人和墨西哥人的子宫癌风险的影响需要紧急调查和有针对性的公共卫生战略.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Disorders of the Female Reproductive System
364
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
364
Hazard Ratio
129
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
129
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355


